They demonstrated that its recombinant version, rLZ-8, induced cycle arrest and apoptosis by downregulating the expression of EGFR and inhibiting EGFR downstream effectors, AKT and ERK1/2 in lung cancer cells. This evidence concerns the gene AKT1 and lung carcinoma.